3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
52
Carcinoma, Renal Cell
47
Neoplasm Metastasis
24
Neoplasms
18
Kidney Neoplasms
18
Neuroendocrine Tumors
17
Carcinoma, Non-Small-Cell Lung
13
Tuberous Sclerosis
12
Stomach Neoplasms
12
Lymphoma, Mantle-Cell
12
Lymphoma, Large B-Cell, Diffuse
11
Recurrence
10
Prostatic Neoplasms
10
Lymphoma
10
Hodgkin Disease
10
Glioblastoma
10
Colorectal Neoplasms
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Brain Neoplasms
9
Lymphoma, Follicular
8
Lung Neoplasms
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Carcinoma
8
Waldenstrom Macroglobulinemia
7
Triple Negative Breast Neoplasms
7
Sarcoma
7
Multiple Myeloma
7
Lymphoma, B-Cell, Marginal Zone
7
Glioma
7
Central Nervous System Neoplasms
7
Interventions
pembrolizumab
2
Imatinib Mesylate
2
Cisplatin
2
Axitinib
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
tislelizumab
1
regorafenib
1
gallium 68 PSMA-11
1
avelumab
1
Tretinoin
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sunitinib
1
Radiation
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nelfinavir
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Immunotherapy
1
GSK-3326595
1
Everolimus
1
Etoposide
1
Endoscopic Mucosal Resection
1
Drug Therapy
1
Doxorubicin
1
Cyclophosphamide
1
Bortezomib
1
Blood Specimen Collection
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Adenoid Cystic
×
Everolimus
×
Clear all
NCT01152840
2015-05-20
ACCRAD001
Seoul National University Hospital
Phase 2
Completed
33 enrolled